Prokineticin 1, homeobox A10, and progesterone receptor messenger ribonucleic acid expression in primary cultures of endometrial stromal cells isolated from endometrium of healthy women and from eutopic endometrium of women with endometriosis

Tiberi, Federica; Tropea, Anna; Romani, Federica; Apa, Rosanna; Marana, Riccardo; Lanzone, Antonio

doi:10.1016/j.fertnstert.2010.03.006

Cited by 16 publications

(13 citation statements)

References 43 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Here we have shown its levels to be elevated in first trimester decidua tissue, where it localizes primarily to the stromal compartment. Recently, PROK1 levels have also been shown to increase in stromal cells decidualized in vitro (Salker et al ., 2010; Tiberi et al ., 2010), and PROK1 is similarly increased in decidua tissue (Evans et al ., 2008). We have found that when the expression of either DKK1 or PROK1 is knocked down in primary endometrial stromal cells, there is a decrease in the expression of the markers of decidualization IGFBP1, PRL and IL11 in response to a decidualizing stimulus.…”

Section: Discussionmentioning

confidence: 99%

Prokineticin 1 induces Dickkopf 1 expression and regulates cell proliferation and decidualization in the human endometrium

Macdonald

Sales

Grant

et al. 2011

Molecular Human Reproduction

View full text Add to dashboard Cite

Prokineticin 1 (PROK1) signalling via prokineticin receptor 1 (PROKR1) regulates the expression of several genes with important roles in endometrial receptivity and implantation. This study investigated PROK1 regulation of Dickkopf 1 (DKK1) expression, a negative regulator of canonical Wnt signalling, and its function in the non-pregnant endometrium and first trimester decidua. DKK1 mRNA expression is elevated during the mid-secretory phase of the menstrual cycle and expression increases further in first trimester decidua. DKK1 protein expression is localized to glandular epithelial and stromal cells during the proliferative, early- and mid-secretory phases, whereas expression is confined to the stroma in the late-secretory phase and first trimester decidua. PROK1 induces the expression of DKK1 in endometrial epithelial cells stably expressing PROKR1 and in first trimester decidua explants, via a Gq-calcium-calcineurin-nuclear factor of activated T-cells-mediated pathway. Endometrial epithelial cell proliferation is negatively regulated by PROK1-PROKR1 signalling. We demonstrate that this effect on cell proliferation occurs via DKK1 expression, as siRNA targeted against DKK1 reduces the PROK1-induced decrease in proliferation. Furthermore, decidualization of primary human endometrial stromal cells with progesterone and cyclic adenosine monophosphate is inhibited by miRNA knock down of PROK1 or DKK1. These data demonstrate important roles for PROK1 and DKK1 during endometrial receptivity and early pregnancy, which include regulation of endometrial cell proliferation and decidualization.

show abstract

Section: Discussionmentioning

confidence: 99%

Prokineticin 1 induces Dickkopf 1 expression and regulates cell proliferation and decidualization in the human endometrium

Macdonald

Sales

Grant

et al. 2011

Molecular Human Reproduction

View full text Add to dashboard Cite

show abstract

“…However, embryos produced from these mice could implant and develop normally in a wild-type surrogate; in contrast, wild-type embryos failed to implant in Hoxa-10-deficient mice (13,14). In humans, defective endometrial HOXA-10 expression during the midsecretory phase have also been associated with endometriosis (15,16), adenomyosis (17), polycystic ovary syndrome (PCOS) (18), submucosal uterine leiomyomas (19), and hydrosalpinges (20), conditions that are associated with abnormal implantation.…”

mentioning

confidence: 99%

HOXA-10 and E-cadherin expression in the endometrium of women with recurrent implantation failure and recurrent miscarriage

Yang

Chen

Saravelos

et al. 2017

Fertility and Sterility

View full text Add to dashboard Cite

show abstract

“…Tiberi et al, extending the previous studies, studied PROK1 mRNA, HOXA10, PR mRNA in primary cultures of ESC from eutopic endometrium of 12 endometriotic patients along with 12 controls to study whether the in vitro steroid hormone dependence of PROK1 gene expression is altered in endometriotic ESC obtained from women with endometriosis in contrast to normal women and they found PROK1 and PR expression was not induced after 1:4 days of treatment with steroid hormones. However, when ESC from both groups of women were differentiated for decidual phenotype, PROK1 mRNA was upregulated and HOXA10 mRNA are downregulated to some extent and especially these results point to P resistance to some extent in cases of endometriosis [73].…”

Section: Role Of Prokineticinsmentioning

confidence: 91%

An Update on Pathophysiology and Medical Management of Endometriosis

Kaur¹,

Allahbadia²

2016

ARSci

View full text Add to dashboard Cite

Endometriosis is an inflammatory oestrogen dependent disease defined by the presence of endometrial glands and stroma at extrauterine sites. The modern advance in treatment of endometriosis management is tackling the debilitating pain it causes, besides the infertility in patients desiring fertility in reproductive age group. This can be achieved by surgical or medical means, although in most cases a combination of both treatments is required. Usually, long term treatment is required in most cases. Unfortunately in most cases, pain symptoms recur between 6months and 12 months once treatment is stopped. A lot of research has gone in understanding the pathogenesis and further medical management of endometriosis besides surgery to be useful in relieving pain and use in patients desiring fertility besides hormonal treatments used earlier like hormonal contraceptives (oral, transdermal or vaginal administration), progestogens, danazol, Gonadotrophic releasing hormone agonist (GnRH), aromatase inhibitors. Newer agents like antiangiogenic drugs, phytochemical agents like resveratrol, TNF-α inhibitors, GnRH antagonists like egalogolix, statins, antiinflammatory agents like COX2 Inhibitors and PPARγ inhibitors like pioglitazone etc., with recent work of combined efficacy of telmesartan of both PPARγ partial agonism along with angiotensin 1 receptor agonism having more efficacy, role of immunomodulators like rapamycin, lipoxin 4 and pentoxyphylline, GnRH antagonists like egalogolix are still under study undergoing phase III trials although preliminary results show promising results with fewer side effects as compared to similar duration of GnRH agonist and much less BMD side effects. Increasing number of trials show the safety of SPRM's, along with efficacy although disadvantage is suppression of fertility so cannot be used for women desiring fertility. Currently, only mifepristone and ulipristal have received FDA approval for indication in fibroid treatment, MTP and not for endometriosis as yet. The advantages and disadvantages of all the recent advances are discussed in an update in the pathophysiology as well medical treatment of endometriosis.

show abstract

Prokineticin 1, homeobox A10, and progesterone receptor messenger ribonucleic acid expression in primary cultures of endometrial stromal cells isolated from endometrium of healthy women and from eutopic endometrium of women with endometriosis

Cited by 16 publications

References 43 publications

Prokineticin 1 induces Dickkopf 1 expression and regulates cell proliferation and decidualization in the human endometrium

Prokineticin 1 induces Dickkopf 1 expression and regulates cell proliferation and decidualization in the human endometrium

HOXA-10 and E-cadherin expression in the endometrium of women with recurrent implantation failure and recurrent miscarriage

An Update on Pathophysiology and Medical Management of Endometriosis

Contact Info

Product

Resources

About